Luteolin for Health & Longevity - Quick Reference Sheet

Luteolin for Health & Longevity

Created on 08/05/2026 – Quick Reference based on Evidence Review created using AI4L / Grok 4 Audit

Luteolin is a plant flavone with laboratory support for calming inflammation and oxidative stress. The clearest human evidence is for combinations with palmitoylethanolamide plus smell training after viral smell loss. Standalone use for broad longevity claims remains under-proven. Usual doses appear well tolerated; product formulation strongly affects how much is absorbed. (Full Review)

Protocol

Dose
100–500 mg/day
Or PEA 700 mg + luteolin 70 mg 1–2× daily for smell recovery
Formulation
Bioavailable form
Liposomal, phytosome, or PEA co-ultramicronized preferred
Start & timing
50–100 mg once daily
Titrate over 1–2 weeks; take with a fat-containing meal
Time to effect
Smell recovery (PEA–luteolin)
Several weeks
With structured olfactory training
Brain fog / inflammation
2–8 weeks
When symptomatic change occurs
Longevity biomarkers
Months
Unproven; any shift unconfirmed

Benefits

Contraindications
  • Pregnancy and breastfeeding (insufficient safety data; avoid)
  • Children except within research or specialist protocols
  • Known allergy to luteolin-containing plants or product excipients
  • Advanced hepatic failure (Child-Pugh Class C) or severe renal impairment without specialist oversight
  • Concurrent narrow-therapeutic-index CYP3A4/CYP1A2/CYP2C9 drugs without monitoring plan
  • Active chemotherapy or targeted cancer therapy without oncology approval
Key Interactions
  • CYP3A4 substrate drugs (e.g., midazolam, certain statins, some calcium-channel blockers, selected immunosuppressants such as tacrolimus/cyclosporine)
  • CYP1A2 substrates (e.g., caffeine, tizanidine, theophylline, some antipsychotics)
  • CYP2C9 substrates (e.g., warfarin, some NSAIDs, sulfonylureas)
  • OATP1B1 / OATP2B1 substrates (e.g., certain statins)
  • Other flavonoids and mast-cell stabilizers (quercetin, apigenin, multi-flavonoid combinations, cromolyn, high-dose PEA)
  • Sedating or CNS-active agents
  • Hormone therapies / progesterone pathways (experimental)

Risk & Side Effects

  • High: [risks_high]
  • Medium: Gastrointestinal discomfort; drug–metabolizing enzyme interactions
  • Low: Progesterone / endocrine pathway interference; high-dose organ toxicity; contaminated or mislabeled products
  • Speculative: Off-target immune suppression with aggressive multi-agent combinations

Monitoring

Marker Target Why
hs-CRP <1.0 mg/L (functional often <0.5–1.0) Tracks systemic inflammatory tone that luteolin aims to influence
ALT / AST ALT ideally <25–30 U/L (sex-dependent); avoid rising trends Hepatic safety with polyphenols and polypharmacy
GGT Lower within lab range; functional often <20–30 U/L Extra hepatic/oxidative stress context
eGFR / creatinine eGFR ≥90 mL/min/1.73 m² preferred; investigate sustained decline Baseline renal clearance context
Fasting glucose / HbA1c Glucose ~70–90 mg/dL; HbA1c ~4.8–5.3% (individualize) Metabolic context if metabolic benefit is a goal
CBC Within lab reference; watch unexpected cytopenias General safety screen
INR (if on warfarin) Per anticoagulation clinic target Detect CYP2C9-related interaction

Cadence: Check-in at 2 weeks (tolerability), 4–8 weeks (early benefit), and 12 weeks (continue vs. stop); labs every 3–6 months if long-term or higher risk

Qualitative Assessment

  • Morning cognitive clarity and afternoon mental fatigue
  • Smell identification/threshold (if post-viral indication)
  • Allergic or histamine-type symptom frequency
  • Training recovery and joint comfort
  • GI tolerance and stool pattern
  • Subjective sense that benefits justify continued cost and daily supplement burden